{"title":"Meda Asserts Independence with US$3.1 B Rottapharm Acquisition","authors":"Heather Cartwright","doi":"10.3833/pdr.v2014i9.2060","DOIUrl":null,"url":null,"abstract":"Having rejected two takeover bids from Mylan earlier in 2014, Sweden’s Meda has agreed to acquire the Italian speciality pharmaceutical company Rottapharm Madaus for a total consideration of SEK21.2 B (US$3.1 B), including net debt of SEK2.8 B (US$407 M). The deal comes only weeks after family owned Rottapharm withdrew a planned IPO citing unfavourable market conditions. The acquisition, the largest in Meda’s history, will bolster the company’s consumer healthcare business and increase its emerging market revenues by 50%.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"172 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2014i9.2060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Having rejected two takeover bids from Mylan earlier in 2014, Sweden’s Meda has agreed to acquire the Italian speciality pharmaceutical company Rottapharm Madaus for a total consideration of SEK21.2 B (US$3.1 B), including net debt of SEK2.8 B (US$407 M). The deal comes only weeks after family owned Rottapharm withdrew a planned IPO citing unfavourable market conditions. The acquisition, the largest in Meda’s history, will bolster the company’s consumer healthcare business and increase its emerging market revenues by 50%.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
